YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing Data update expected in 2027, with trial completion in 2028 Trial-in-progress poster to be presented at ESMO…
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins’ ability to match target and disease biology for improved outcomes ZURICH…
(RTTNews) - Molecular Partners AG (MOLN), a clinical-stage biotech company, provided an update on its pipeline of targeted alpha-Radio-Designed Ankyrin Repeat Protein (DARPin) therapeutics. Company Profile and Pipeline Molecular Partners d…
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027Additional com…
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive effi…
The European market has recently shown a lack of direction, with the pan-European STOXX Europe 600 Index experiencing a slight decline as investors weigh geopolitical developments and economic data. Despite this uncertainty, penny stocks r…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LRMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of cust…
This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Eckert & Ziegler SE (XTER:EUZ) reported a 7% increase…
The European market has shown resilience, with the pan-European STOXX Europe 600 Index ending the week slightly up amid ongoing geopolitical uncertainties and fluctuating oil prices. In this context, investors often seek opportunities in l…
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin the…
Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including check…
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin candidate in on-going U…
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177Lu or 203Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass.,…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin t…
Molecular Partners Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026 Second…
Petroleo Brasileiro S.A., or Petrobras PBR, is set to release fourth-quarter 2025 results on March 5. The Zacks Consensus Estimate for the to-be-reported quarter is a profit of 57 cents per share on revenues of $23.1 billion. Let’s delve i…
Molecular Partners Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac) ZURICH-SCHLIEREN, Switz…
As the European market shows signs of modest recovery, with the pan-European STOXX Europe 600 Index gaining 0.44% amidst mixed performances across major indices, investors are cautiously optimistic about future growth prospects. In such a…
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emit…
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026 Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026 Phase 2 in…
European markets have shown robust performance, with the pan-European STOXX Europe 600 Index reaching a new high and closing 2025 with its strongest annual return since 2021. For investors interested in smaller or newer companies, penny st…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin ther…
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens Accelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of cust…
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN…
IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program t…
The European market has shown resilience, with major stock indexes like the STOXX Europe 600 and Germany's DAX posting gains, reflecting a broader trend of economic recovery and consumer confidence. In such an environment, investors often…
MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first rad…
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announceme…
Molecular Partners Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -…
European markets have recently experienced a boost, with the pan-European STOXX Europe 600 Index rising by 1.18% amid easing trade tensions and optimism over potential U.S. interest rate cuts. In this context, penny stocks—often smaller or…
Molecular Partners' MP0726, a Radio-DARPin targeting mesothelin, shows promising preclinical results for ovarian cancer treatment. Quiver AI Summary Molecular Partners AG and Orano Med have announced the development of MP0726, a Radio-DARP…
Molecular Partners (NASDAQ:MOLN [https://seekingalpha.com/symbol/MOLN]) said that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen t…
Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of actio…
MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of t…
MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to dateEmerging evidence of antitumor activity…